Press Releases

Press Releases

Date Title View
September 20, 2018 Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections
September 19, 2018 Tetraphase Pharmaceuticals to Present XERAVA™ (Eravacycline) and TP-6076 Data at IDWeek 2018
August 27, 2018 Tetraphase Pharmaceuticals Announces FDA Approval of XERAVA™ (Eravacycline) for Complicated Intra-Abdominal Infections (cIAI)
August 27, 2018 Tetraphase Pharmaceuticals to Participate at Upcoming Investor Conference
August 2, 2018 Tetraphase Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Highlights
July 27, 2018 Tetraphase Pharmaceuticals Receives Positive CHMP Opinion for Xerava™ (eravacycline) as a Treatment for Complicated Intra-Abdominal Infections
July 12, 2018 Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
June 11, 2018 Tetraphase Pharmaceuticals Announces Data from a Pooled Analysis of IGNITE1 and IGNITE4 Phase 3 Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections at the ASM Microbe 2018 Annual Meeting
June 8, 2018 Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
June 4, 2018 Tetraphase Pharmaceuticals Announces Everest Medicines’ Submission of an Investigational New Drug Application for Eravacycline in Complicated Intra-Abdominal Infection to the China Food and Drug Administration
Displaying 1 - 10 of 24
Contact Us

Tetraphase Pharmaceuticals, 480 Arsenal Way, Suite 110, Watertown, MA 02472

Tel 617-715-3600 | Fax 617-926-3557 | CONTACT AND MEDICAL INFORMATION

Forward Looking Statements | Terms of Use | Privacy Policy

Copyright © Tetraphase Pharmaceuticals       All rights reserved.

To:

Please enter a valid email address.

From:

Please enter a valid email address.

 

Share information about Tetraphase

Cancel

Thank you! Your email has been sent.